erlotinib hydrochloride has been researched along with tipifarnib in 3 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 309 | 92 | 94 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | tipifarnib (IC50) |
|---|---|---|---|
| Chain B, Protein farnesyltransferase beta subunit | Rattus norvegicus (Norway rat) | 0.0007 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 2.88 | |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Bos taurus (cattle) | 0.5503 | |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Homo sapiens (human) | 2.2237 | |
| Protein farnesyltransferase subunit beta | Bos taurus (cattle) | 0.0006 | |
| Protein farnesyltransferase subunit beta | Homo sapiens (human) | 0.0019 | |
| Geranylgeranyl transferase type-1 subunit beta | Homo sapiens (human) | 10 | |
| Geranylgeranyl transferase type-1 subunit beta | Bos taurus (cattle) | 1.1 | |
| Protein farnesyltransferase alpha subunit | Plasmodium falciparum (malaria parasite P. falciparum) | 0.017 | |
| CAAX farnesyltransferase subunit beta | Plasmodium falciparum (malaria parasite P. falciparum) | 0.017 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sánchez De Cos Escuín, J | 1 |
| Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN | 1 |
| Adjei, A; Allred, J; Goetz, M; Jazieh, K; Kaufmann, SH; Lim, VS; Molina, J; Reid, J; Yin, J | 1 |
2 review(s) available for erlotinib hydrochloride and tipifarnib
| Article | Year |
|---|---|
[New therapeutic targets and strategies in lung cancer].
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Benzodiazepines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endothelial Growth Factors; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Metalloendopeptidases; Multicenter Studies as Topic; Piperazines; Polyisoprenyl Phosphates; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolones; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sesquiterpenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
[Problems in the current target therapy of malignancies].
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab | 2005 |
1 trial(s) available for erlotinib hydrochloride and tipifarnib
| Article | Year |
|---|---|
A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Quinolones; Salvage Therapy; Tissue Distribution | 2019 |